サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1696288

デジタル糖尿病管理の世界市場（2025年～2033年）

Global Digital Diabetes Management Market - 2025-2033

出版日
ページ情報
英文 180 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.28円
デジタル糖尿病管理の世界市場（2025年～2033年）
出版日: 2025年03月25日
発行: DataM Intelligence
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のデジタル糖尿病管理の市場規模は、2024年に145億8,000万米ドルに達し、2033年までに332億6,000万米ドルに達すると予測され、2025年～2033年の予測期間にCAGRで9.7%の成長が見込まれます。

世界のデジタル糖尿病管理市場は、デバイス、ソフトウェア、サービスなどのデジタル技術を活用して糖尿病管理とモニタリングを向上させます。これには、持続血糖モニター（CGM）、インスリンポンプ、モバイルアプリ、クラウドベースプラットフォームなどのツールが含まれます。これらの技術は、患者の健康指標に関するデータを収集、分析、共有するために連携し、患者や医療提供者が糖尿病管理について十分な情報に基づいた意思決定を行えるようにするリアルタイムの知見を提供します。この市場は、患者が血糖値をよりよくコントロールし、合併症を減らし、全体的な健康転帰を向上できるようにすることを目指しています。

市場力学

促進要因と抑制要因

糖尿病デジタルヘルスにおける技術の進歩

技術の進歩は、デジタル糖尿病管理市場の成長を促進する上で重要な役割を果たしています。持続血糖モニター（CGM）、スマートインスリンポンプ、ウェアラブルデバイス、AIを搭載した糖尿病管理アプリなどの技術革新は、糖尿病をモニタリングし管理する方法を変革しています。これらの技術は、血糖値に関するリアルタイムの個別化されたデータを提供し、患者や医療提供者がよりよい情報に基づいた意思決定を行うことを可能にします。例えば、AIとビッグデータアナリティクスは、インスリン投与アルゴリズムの改良と個別化された治療推奨の提供に役立ち、短期および長期の糖尿病管理を向上させます。

技術の進歩は、糖尿病を管理するための効果的なツールを提供することで、糖尿病治療に革命をもたらしています。重要な焦点の1つが、常に最適な血糖値を維持することです。コネクテッドインスリンペン、コネクテッドA1Cモニター、モバイルアプリなどのデジタルヘルスツールにより、患者は病院以外の場所でも糖尿病を管理しやすくなっています。これらのモバイルアプリケーションにより、医療提供者はリアルタイムのデータに基づいて個別化された治療計画を作成することができ、血糖値の良好なコントロールを確保し、長期的な健康リスクを低減できる可能性があります。

糖尿病管理におけるもう1つの画期的な進歩は、自動インスリン投与（AID）システムです。このシステムは、持続血糖モニター（CGM）とインスリンポンプを組み合わせ、リアルタイムの血糖データに基づいてインスリンレベルを自動的に調整します。このシステムは、血糖値をより正確にコントロールし、患者の負担を軽減します。さらに、ポータブルA1Cモニターは、個人が自宅でA1C値を測定することを可能にし、長期的な糖尿病コントロールの評価に不可欠な指標を提供します。これらの進歩は、個別化医療に大きく寄与し、患者が通院回数を減らしながら病状をよりよく管理できるようにします。

例えば、Kakao Healthcareは2024年2月、PASTA（Personalized、Accessible、Supportive、Tech-enabled、Affordable）と呼ばれるAIを搭載した新しい糖尿病管理アプリを発表しました。このアプリは、糖尿病やその他の慢性疾患を持つ人々が、より効果的に健康管理を行えるように設計されています。また、i-SENSのCareSens AirやDexcomのG7などの持続血糖モニタリング（CGM）デバイスと統合され、血糖値のリアルタイムデータを提供します。これらすべての要因が、世界のデジタル糖尿病管理市場に需要をもたらしています。

デバイスと技術の高いコスト

デバイスと技術の高いコストは、依然として世界のデジタル糖尿病管理市場の大きな抑制要因となっています。2024年7月のNational Center for Biotechnology Information（NCBI）のデータによると、インスリンポンプ、持続血糖モニター（CGM）、その他の先進のデジタルツールはかなり高額なことがあり、一部のインスリンポンプは、関連する消耗品を含めないで4,500米ドル～6,500米ドルです。この価格設定は、特に健康保険に加入していない患者にとっては障壁となり、不可欠な糖尿病管理技術へのアクセスを制限することになります。

当レポートでは、世界のデジタル糖尿病管理市場について調査し、市場力学、地域とセグメントの分析、競合情勢、企業プロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 エグゼクティブインサイトと重要事項

  • 市場のハイライトと戦略的ポイント
  • 主要動向と将来の予測
  • 抜粋：製品タイプ別
  • 抜粋：モダリティ別
  • 抜粋：エンドユーザー別
  • 抜粋：地域別

第3章 市場力学

  • 影響要因
    • 促進要因
      • 糖尿病デジタルヘルスにおける技術の進歩
      • 糖尿病の有病率の上昇
    • 抑制要因
      • デバイスと技術の高いコスト
      • データのプライバシーとセキュリティに関する懸念
    • 機会
      • 新興市場への進出
    • 影響の分析

第4章 戦略的考察と産業の見通し

  • マーケットリーダーとパイオニア
    • 新興パイオニアと著名企業
    • 確立されたリーダーともっとも売れているブランド
    • マーケットリーダーと確立された製品
  • CXOの視点
  • 最新の発展とブレークスルー
  • ケーススタディ/進行中の調査
  • 規制と償還の情勢
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 特許分析
  • SWOT分析
  • アンメットニーズとギャップ
  • 市場参入と拡大に対し推奨される戦略
  • シナリオ分析：ベストケース、ベースケース、ワーストケースの予測
  • 価格分析と価格動向
  • キーオピニオンリーダー

第5章 デジタル糖尿病管理市場：製品タイプ別

  • スマート血糖測定器
  • 持続血糖モニタリング（CGM）システム
  • スマートインスリンペン
  • スマートインスリンポンプ
  • インスリンパッチ、閉ループポンプ
  • その他

第6章 デジタル糖尿病管理市場：モダリティ別

  • ウェアラブル
  • ハンドヘルド

第7章 デジタル糖尿病管理市場：エンドユーザー別

  • 在宅ケア環境
  • 病院、糖尿病クリニック
  • その他

第8章 デジタル糖尿病管理市場：地域別、市場の分析と成長機会

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他の欧州
  • ラテンアメリカ
    • メキシコ
    • ブラジル
    • アルゼンチン
    • その他のラテンアメリカ
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他のアジア太平洋
  • 中東・アフリカ

第9章 競合情勢と市場ポジショニング

  • 競合情勢の概要と主要市場企業
  • 市場シェア分析とポジショニングマトリクス
  • 戦略的パートナーシップ、合併・買収
  • 製品ポートフォリオとイノベーションにおける主な発展
  • 企業ベンチマーク

第10章 企業プロファイル

  • Abbott
  • Dexcom, Inc.
  • F. Hoffmann-La Roche Ltd
  • Medtronic
  • Insulet Corporation.
  • Tandem Diabetes Care, Inc.
  • Ascensia Diabetes Care Holdings AG.
  • LifeScan IP Holdings, LLC.
  • AgaMatrix
  • Ypsomed AG (LIST NOT EXHAUSTIVE)

第11章 前提条件と調査手法

第12章 付録

目次
Product Code: MD2392

The global digital diabetes management market reached US$ 14.58 billion in 2024 and is expected to reach US$ 33.26 billion by 2033, growing at a CAGR of 9.7 % during the forecast period of 2025-2033.

The global digital diabetes management market leverages digital technologies, such as devices, software, and services, to improve diabetes management and monitoring. This includes tools like continuous glucose monitors (CGMs), insulin pumps, mobile apps, and cloud-based platforms. These technologies work together to collect, analyze, and share data on a patient's health metrics, providing real-time insights that enable patients and healthcare providers to make informed decisions about diabetes management. The market aims to empower patients to control their glucose levels better, reduce complications, and improve overall health outcomes.

Market Dynamics: Drivers & Restraints

Technological Advancements in Diabetes Digital Health

Technological advancements play a key role in driving the growth of the digital diabetes management market. Innovations such as continuous glucose monitors (CGMs), smart insulin pumps, wearable devices, and AI-powered diabetes management apps are transforming how diabetes is monitored and managed. These technologies provide real-time, personalized data on blood glucose levels, enabling patients and healthcare providers to make better-informed decisions. For instance, AI and big data analytics help refine insulin delivery algorithms and offer individualized treatment recommendations, improving both short- and long-term diabetes management.

Technological advancements are revolutionizing diabetes care by providing effective tools for managing the condition. One key focus is maintaining optimal glucose levels consistently. Digital health tools, including connected insulin pens, portable A1C monitors, and mobile apps, are making it easier for patients to manage their diabetes outside of hospital settings. These mobile applications allow healthcare providers to create personalized treatment plans based on real-time data, ensuring better control over blood glucose levels and potentially reducing long-term health risks.

Another breakthrough in diabetes management is the automated insulin delivery (AID) system, which combines continuous glucose monitors (CGMs) and insulin pumps to automatically adjust insulin levels based on real-time glucose data. This system offers more precise control over blood sugar levels, reducing the burden on patients. Additionally, portable A1C monitors allow individuals to measure their A1C levels at home, providing an essential marker for assessing long-term diabetes control. These advancements contribute significantly to personalized care, enabling patients to better manage their condition with fewer hospital visits.

For instance, in February 2024, Kakao Healthcare launched a new AI-powered diabetes management app called PASTA (Personalized, Accessible, Supportive, Tech-enabled, and Affordable). This app is designed to help people with diabetes and other chronic conditions manage their health more effectively. It integrates with continuous glucose monitoring (CGM) devices, such as i-SENS's CareSens Air and Dexcom's G7, to provide real-time data on blood glucose levels. All these factors demand the global digital diabetes management market.

High Cost of Devices and Technology

The high cost of devices and technology remains a significant restraint in the global digital diabetes management market. Insulin pumps, continuous glucose monitors (CGMs), and other advanced digital tools can be quite expensive, as per National Center for Biotechnology Information (NCBI) data in July 2024, with some insulin pumps costing between $4,500 and $6,500, not including associated consumables. This price tag can be a barrier for patients, especially those without health insurance, limiting their access to essential diabetes management technology.

Moreover, although these devices improve patient outcomes by providing real-time data and better control over glucose levels, studies have shown that insulin pumps may not always be the most cost-effective option compared to multiple daily injections (MDI), especially for those with type 1 diabetes. As a result, the global diabetes management market is expanding rapidly. The above factors are limiting the market growth.

Segment Analysis

The global digital diabetes management market is segmented based on product type, modality, end-user, and region.

Product Type:

The continuous glucose monitoring (CGM) systems segment from product type is expected to dominate the digital diabetes management market with the highest market share

Continuous glucose monitoring (CGM) systems are a major driver of the growth in the global digital diabetes management market. These devices enable patients to monitor their glucose levels in real time throughout the day without the need for frequent fingerstick testing. CGMs provide critical data on glucose fluctuations, offering patients a comprehensive view of their glucose patterns. This real-time data helps individuals with diabetes make more informed decisions about their insulin dosage, diet, and exercise, contributing to better control over blood sugar levels and fewer complications in the long run.

The increasing accuracy, affordability, and convenience of CGMs have significantly boosted their adoption, especially as these devices now integrate with other diabetes management tools, like insulin pumps and mobile apps. Many CGM systems are now more compact, with advanced features such as alarms for high or low glucose levels, and they often work wirelessly with smartphones, providing patients with accessible and personalized management options.

As more people seek non-invasive, continuous monitoring options, CGMs are becoming a key element in both type 1 and type 2 diabetes management. Their widespread use is a major factor driving the expansion of the digital diabetes management market, particularly as healthcare providers leverage data from CGMs to improve treatment outcomes and patient engagement.

For instance, in August 2024, Medtronic announced FDA approval for its Simplera continuous glucose monitor (CGM), marking a significant innovation in diabetes care. Simplera is Medtronic's first all-in-one, disposable CGM that is half the size of its previous models. Designed for simplicity, it features an easy two-step insertion process, making it ideal for individuals using multiple daily insulin injections (MDI).

It eliminates the need for overtape, offering a more discreet and comfortable wear experience. Additionally, the Simplera system integrates seamlessly with the InPen smart insulin pen and is compatible with Medtronic's MiniMed 780G automated insulin delivery system. These factors have solidified the segment's position in the global digital diabetes management market.

Geographical Analysis

North America is expected to hold a significant position in the global digital diabetes management market with the highest market share

The high prevalence of diabetes in the United States, with nearly 16% of adults diagnosed according to the Centers for Disease Control and Prevention (CDC), is a significant driving factor for the growth of the North American digital diabetes management market.

As the number of diabetes cases continues to rise, there is an increasing demand for effective, efficient, and accessible management solutions. Digital health technologies, such as continuous glucose monitoring (CGM) systems, smart insulin pumps, and mobile apps, offer patients real-time data and personalized feedback that can significantly improve diabetes control, reducing complications associated with the disease.

The integration of AI and machine learning into diabetes management devices allows for smarter, more personalized treatment. These technologies help optimize insulin dosing, offer predictive insights, and reduce the frequency of diabetes-related complications. Moreover, the development of wearable devices, such as insulin pumps and glucose sensors, that are more user-friendly and connected to mobile apps enhances patient engagement and self-management.

For instance, in February 2025, Owens & Minor launched the ByramConnect digital health platform, designed to assist individuals with diabetes and other chronic health conditions. This platform is powered by the Welldoc App, which uses artificial intelligence to provide personalized coaching, self-tracking, and clinically relevant insights. It helps individuals manage conditions like type 1 and type 2 diabetes, as well as related conditions such as hypertension, cardiovascular risks, and weight management

Competitive Landscape

The major global players in the digital diabetes management market include Abbott, Dexcom, Inc., F. Hoffmann-La Roche Ltd, Medtronic, and Insulet Corporation. Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG., LifeScan IP Holdings, LLC., AgaMatrix, and Ypsomed AG among others.

Key Developments

  • In August 2024, Insulet Corporation's Omnipod 5 Automated Insulin Delivery System was FDA-cleared for use by adults with type 2 diabetes, making it the first and only tubeless automated insulin delivery (AID) system approved for both type 1 and type 2 diabetes management.
  • In December 2023, Tandem Diabetes Care launched the full U.S. rollout of its revamped diabetes management platform, Tandem Source. This platform integrates several features from its previous systems, such as t:connect and t:connect HCP, and combines them with enhanced data reporting tools.
  • In August 2023, Welldoc, a digital health leader revolutionizing chronic care, announced the receipt of its 11th 510(k) clearance from the Food and Drug Administration (FDA) for its award-winning diabetes digital health solution, BlueStar. This clearance immediately follows Welldoc's 10th 510(k) clearance announcement earlier this month, solidifying the company's continued leadership in chronic care innovation.
  • In August 2023, Nemaura Medical's sugarBEAT received approval from the Saudi Food and Drug Authority (SFDA), marking a significant milestone in the Middle East market. This wearable, non-invasive glucose sensor offers continuous glucose monitoring (CGM) for diabetes and pre-diabetes management.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global digital diabetes management market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Modality
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Technological Advancements in Diabetes Digital Health
      • 3.1.1.2. Rising Prevalence of Diabetes
    • 3.1.2. Restraints
      • 3.1.2.1. High Cost of Devices and Technology
      • 3.1.2.2. Data Privacy and Security Concerns
    • 3.1.3. Opportunity
      • 3.1.3.1. Expansion in Emerging Markets
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest-selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. CXO Perspectives
  • 4.3. Latest Developments and Breakthroughs
  • 4.4. Case Studies/Ongoing Research
  • 4.5. Regulatory and Reimbursement Landscape
    • 4.5.1. North America
    • 4.5.2. Europe
    • 4.5.3. Asia Pacific
    • 4.5.4. Latin America
    • 4.5.5. Middle East & Africa
  • 4.6. Porter's Five Forces Analysis
  • 4.7. Supply Chain Analysis
  • 4.8. Patent Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics
  • 4.14. Key Opinion Leaders

5. Digital Diabetes Management Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Smart Glucose Meters*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Continuous Glucose Monitoring (CGM) Systems
  • 5.4. Smart Insulin Pens
  • 5.5. Smart Insulin Pumps
  • 5.6. Insulin Patches and Closed-loop Pumps
  • 5.7. Others

6. Digital Diabetes Management Market, By Modality

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 6.1.2. Market Attractiveness Index, By Modality
  • 6.2. Wearable*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Handheld

7. Digital Diabetes Management Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Home Care Settings*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Hospitals and Diabetes Clinics
  • 7.4. Others

8. Digital Diabetes Management Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. Latin America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Mexico
      • 8.4.6.2. Brazil
      • 8.4.6.3. Argentina
      • 8.4.6.4. Rest of Latin America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Abbott*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio
      • 10.1.2.1. Product Description
      • 10.1.2.2. Product Key Performance Indicators (KPIs)
      • 10.1.2.3. Historic and Forecasted Product Sales
      • 10.1.2.4. Product Sales Volume
  • 10.2. Financial Overview
    • 10.2.1. Company Revenue
      • 10.2.1.1. Geographical Revenue Shares
      • 10.2.1.1.1. Revenue Forecasts
      • 10.2.1.2. Key Developments
      • 10.2.1.2.1. Mergers & Acquisitions
      • 10.2.1.2.2. Key Product Development Activities
      • 10.2.1.2.3. Regulatory Approvals, etc.
      • 10.2.1.3. SWOT Analysis
    • 10.2.2. Dexcom, Inc.
    • 10.2.3. F. Hoffmann-La Roche Ltd
    • 10.2.4. Medtronic
    • 10.2.5. Insulet Corporation.
    • 10.2.6. Tandem Diabetes Care, Inc.
    • 10.2.7. Ascensia Diabetes Care Holdings AG.
    • 10.2.8. LifeScan IP Holdings, LLC.
    • 10.2.9. AgaMatrix
    • 10.2.10. Ypsomed AG (LIST NOT EXHAUSTIVE)

11. Assumptions and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us